Podofilox
Condylox, Podofilox (podofilox) is a small molecule pharmaceutical. Podofilox was first approved as Condylox on 1990-12-13. It is used to treat warts in the USA. The pharmaceutical is active against insulin-like growth factor 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Condylox, Podofilox (discontinued: Podofilox)
Drug Products
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06B: Chemotherapeutics for topical use
— D06BB: Antivirals, topical
— D06BB04: Podophyllotoxin
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01C: Plant alkaloids and other natural products, antineoplastic drugs
— L01CB: Podophyllotoxin derivatives, antineoplastic drugs
HCPCS
No data
Clinical
Clinical Trials
1415 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 84 | 280 | 70 | 8 | 17 | 407 |
| Leukemia | D007938 | — | C95 | 57 | 112 | 62 | 6 | 9 | 216 |
| Small cell lung carcinoma | D055752 | — | — | 45 | 119 | 45 | 2 | 4 | 194 |
| Lung neoplasms | D008175 | — | C34.90 | 53 | 111 | 39 | 2 | 1 | 182 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 45 | 126 | 27 | 1 | 5 | 172 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 28 | 61 | 34 | 8 | 8 | 123 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 40 | 66 | 15 | 1 | 5 | 108 |
| B-cell lymphoma | D016393 | — | — | 40 | 60 | 13 | 1 | 4 | 96 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 35 | 44 | 26 | 1 | 2 | 94 |
| Lymphoid leukemia | D007945 | — | C91 | 9 | 33 | 20 | 4 | 3 | 62 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 43 | 44 | 14 | — | 5 | 95 |
| Hodgkin disease | D006689 | — | C81 | 21 | 65 | 20 | — | 4 | 93 |
| Myeloid leukemia | D007951 | — | C92 | 27 | 36 | 22 | — | 2 | 76 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 15 | 28 | 17 | — | 4 | 62 |
| Non-small-cell lung carcinoma | D002289 | — | — | 16 | 34 | 15 | — | 1 | 60 |
| Multiple myeloma | D009101 | — | C90.0 | 7 | 34 | 7 | — | 5 | 52 |
| Sarcoma | D012509 | — | — | 9 | 22 | 15 | — | 5 | 49 |
| Myelodysplastic syndromes | D009190 | — | D46 | 18 | 20 | 13 | — | 1 | 47 |
| Recurrence | D012008 | — | — | 19 | 28 | 4 | — | 4 | 47 |
| Plasma cell neoplasms | D054219 | — | — | 6 | 27 | 6 | — | 4 | 42 |
Show 111 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 8 | 15 | — | — | 3 | 23 |
| Plasmacytoma | D010954 | — | C90.3 | 4 | 13 | — | — | 2 | 19 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 6 | 9 | — | — | 3 | 15 |
| Waldenstrom macroglobulinemia | D008258 | — | C88.0 | 5 | 7 | — | — | 3 | 13 |
| Hematologic neoplasms | D019337 | — | — | 6 | 3 | — | — | 2 | 11 |
| Aids-related lymphoma | D016483 | EFO_1001365 | — | 3 | 6 | — | — | 1 | 10 |
| Graft vs host disease | D006086 | — | D89.81 | 2 | 5 | — | — | 3 | 10 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 5 | 2 | — | — | 3 | 9 |
| Mycosis fungoides | D009182 | — | C84.0 | 5 | 3 | — | — | 2 | 9 |
| Lymphomatoid granulomatosis | D008230 | — | C83.8 | 4 | 4 | — | — | 3 | 9 |
Show 116 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Large granular lymphocytic leukemia | D054066 | — | — | 2 | — | — | — | 2 | 4 |
| Urologic neoplasms | D014571 | — | C64-C68 | 2 | — | — | — | — | 2 |
| Mesothelioma | D008654 | — | C45 | 2 | — | — | — | — | 2 |
| Myeloid leukemia accelerated phase | D015465 | — | — | 2 | — | — | — | — | 2 |
| Melanoma | D008545 | — | — | 2 | — | — | — | — | 2 |
| Neuroepithelial neoplasms | D018302 | — | — | 1 | — | — | — | — | 1 |
| Urethral neoplasms | D014523 | EFO_0003846 | — | 1 | — | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | 1 | — | — | — | — | 1 |
| Deltaretrovirus infections | D006800 | EFO_1001303 | — | 1 | — | — | — | — | 1 |
| Htlv-i infections | D015490 | EFO_0007316 | — | 1 | — | — | — | — | 1 |
Show 15 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chediak-higashi syndrome | D002609 | Orphanet_167 | D72.0 | — | — | — | — | 2 | 2 |
| Ataxia | D001259 | — | R27.0 | — | — | — | — | 1 | 1 |
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | — | — | — | — | 1 | 1 |
| Telangiectasis | D013684 | — | — | — | — | — | — | 1 | 1 |
| Cerebellar ataxia | D002524 | — | — | — | — | — | — | 1 | 1 |
| Wiskott-aldrich syndrome | D014923 | EFO_0003903 | D82.0 | — | — | — | — | 1 | 1 |
| Severe combined immunodeficiency | D016511 | — | D81.0 | — | — | — | — | 1 | 1 |
| Chronic granulomatous disease | D006105 | EFO_0000338 | D71 | — | — | — | — | 1 | 1 |
| Immunologic deficiency syndromes | D007153 | — | D84.9 | — | — | — | — | 1 | 1 |
| Agammaglobulinemia | D000361 | — | D80.1 | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Podofilox |
| INN | — |
| Description | Podophyllotoxin is an organic heterotetracyclic compound that has a furonaphthodioxole skeleton bearing a 3,4,5-trimethoxyphenyl substituent. It is found in the roots and rhizomes of Podophyllum species and is used for the topical treatment of genital warts. It has a role as an antineoplastic agent, a keratolytic drug, a tubulin modulator, a microtubule-destabilising agent, an antimitotic and a plant metabolite. It is a furonaphthodioxole, a lignan and an organic heterotetracyclic compound. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC |
Target
Agency Approved
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Podofilox
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,328 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
105 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use